Combined androgen blockade in the treatment of advanced prostate cancer--an overview. The Scandinavian Prostatic Cancer Group.
The value of combined androgen blockade in the treatment of patients with advanced prostate cancer is still controversial. In this review by the Scandinavian Prostatic Cancer Group, the literature addressing the concept and its clinical use is critically reviewed.
Iversen
P
P
Department of Urology 2112, Rigshospitalet, University of Copenhagen, Denmark.
D000726:Androgen Antagonists / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011292:Premedication; D011467:Prostate / Q000473:pathology; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016032:Randomized Controlled Trials as Topic; D013737:Testis / Q000473:pathology; D013739:Testosterone / Q000031:analogs & derivatives / Q000378:metabolism
D000726:Androgen Antagonists; D013739:Testosterone; C013915:boldenone